Home › Amgen says Kyprolis doubles progression-free survival vs Velcade
 

Keywords :   


Amgen says Kyprolis doubles progression-free survival vs Velcade

2015-03-02 04:09:37| Biotech - Topix.net

Amgen Inc's Kyprolis helped patients with relapsed multiple myeloma live twice as long before their blood cancer worsened compared to a regimen containing rival drug Velcade, according to an interim analysis announced by the company on Sunday. REUTERS: Amgen Inc's Kyprolis helped patients with relapsed multiple myeloma live twice as long before their blood cancer worsened compared to a regimen containing rival drug Velcade, according to an interim analysis announced by the company on Sunday.

Tags: survival doubles amgen progressionfree survival

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
04.07Hurricane Beryl Graphics
04.07Hurricane Beryl Forecast Discussion Number 25
04.07Hurricane Beryl Public Advisory Number 25
04.07Summary for Hurricane Beryl (AT2/AL022024)
04.07Hurricane Beryl Wind Speed Probabilities Number 25
04.07Hurricane Beryl Forecast Advisory Number 25
04.07Tropical Storm Aletta Graphics
04.07Tropical Storm Aletta Forecast Discussion Number 2
More »